The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting a critical milestone in rare disease therapeutics, Pharvaris announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant IR capsules for the on-demand treatment of hereditary angioedema (HAE) attacks. The FDA has established a PDUFA target action date of April 23, 2027, for the final regulatory decision. This acceptance marks a significant de-risking event for the company, providing a clear regulatory pathway for its lead candidate.
This development occurs amid intensifying competition in the HAE sector, where Pharvaris faces peers like BioCryst Pharmaceuticals, which currently markets the oral treatment Orladeyo. Per market data, the progress of deucrictibant is pivotal as the global HAE treatment market is projected to exceed $4 billion by 2028 (per Grand View Research). The acceptance of the NDA validates the clinical data submitted and positions the company to potentially capture a significant share of the oral therapy market.
Regarding market performance, PHVS stood at $33.86 (at close July 2, 2026), having traded between a day low of $33.16 and a high of $34.77. Investors will now monitor the regulatory review process closely. While the upcoming economic calendar does not list immediate sector-specific catalysts, the focus remains on the long-term PDUFA deadline and any interim communications from the FDA regarding the application's status.